Skip to main content

SCYX

Stock
Health Care
Drug Manufacturers - Specialty & Generic

Performance overview

SCYX Price
Price Chart

Forward-looking statistics

Beta
1.05
Risk
70.42%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

scynexis, inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. we are developing our lead product candidate, scy-078, a novel antifungal in phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.

Company info

SectorHealth Care
IndustryDrug Manufacturers - Specialty & Generic
Employees55
Market cap$83.9M

Fundamentals

Enterprise value-$11.8M
Revenue$2.6M
Revenue per employee
Profit margin100.00%
Debt to equity4.92

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.56
Dividend per share
Revenue per share$0.05
Avg trading volume (30 day)$125K
Avg trading volume (10 day)$97K
Put-call ratio

Macro factor sensitivity

Growth-2.4
Credit+6.0
Liquidity+4.3
Inflation-4.7
Commodities-1.9
Interest Rates-2.7

Valuation

Dividend yield0.00%
PEG Ratio4.88
Price to sales10.85
P/E Ratio4.88
Enterprise Value to Revenue-4.48
Price to book0.56

Upcoming events

Next earnings dayMay 16, 2025
Next dividend day
Ex. dividend day

News

SCYNEXIS (SCYX) Skyrockets 134% Year to Date: Here's Why

SCYNEXIS' (SCYX) shares soar 134% year to date, owing to partnership with big wig GSK plc for the development of its antifungal tablet, Brexafemme.

Zacks Investment Research (September 4, 2023)
Scynexis's Oral Ibrexafungerp Shows Potency Against Severe Fungal Infections

SCYNEXIS Inc (NASDAQ: SCYX) has announced interim data from its ongoing Phase 3 FURI and CARES studies of ibrexafungerp in severe fungal infections. FURI study included fungal infections patients who are either intolerant to standard antifungal therapy or experience refractory.

Benzinga (April 22, 2022)
'The Big Short' investor Michael Burry revealed a stake in a tiny biotech company last week that has since soared 42%

Burry's $1 million position in Scynexis led to a $40 million increase in the company's market cap to $170 million.

Business Insider (November 22, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free